Mizuno Y - Search Results

1

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. Dubois B, et al. Among authors: mizuno y. Mov Disord. 2007 Dec;22(16):2314-24. doi: 10.1002/mds.21844. Mov Disord. 2007. PMID: 18098298 Review.

2

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.

Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Schapira AH, et al. Among authors: mizuno y. Mov Disord. 2010 Aug 15;25(11):1627-32. doi: 10.1002/mds.23143. Mov Disord. 2010. PMID: 20544810 Clinical Trial.

3

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Hauser RA, et al. Among authors: mizuno y. Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317. Mov Disord. 2010. PMID: 20669317 Clinical Trial.

4

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.

Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C; Pramipexole Switch Study Group. Rascol O, et al. Among authors: mizuno y. Mov Disord. 2010 Oct 30;25(14):2326-32. doi: 10.1002/mds.23262. Mov Disord. 2010. PMID: 20669265 Clinical Trial.

5

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease.

Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. Antonini A, et al. Among authors: mizuno y. Lancet Neurol. 2009 Oct;8(10):929-37. doi: 10.1016/S1474-4422(09)70225-X. Epub 2009 Aug 24. Lancet Neurol. 2009. PMID: 19709931 Review.

6

Recessive Parkinson's disease.

Kubo S, Hattori N, Mizuno Y. Kubo S, et al. Among authors: mizuno y. Mov Disord. 2006 Jul;21(7):885-93. doi: 10.1002/mds.20841. Mov Disord. 2006. PMID: 16615060 Review.

7

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.

Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H, Kowa H; Japanese Pramipexole Study Group. Mizuno Y, et al. Mov Disord. 2003 Oct;18(10):1149-56. doi: 10.1002/mds.10508. Mov Disord. 2003. PMID: 14534919 Clinical Trial.

8

Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.

Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, Mochizuki H, Hattori N, Mori H, Mizuno Y; Juntendo Parkinson Study Group. Sato K, et al. Among authors: mizuno y. Mov Disord. 2006 Sep;21(9):1384-95. doi: 10.1002/mds.20993. Mov Disord. 2006. PMID: 16763980

9

[Progress in Parkinson's disease].

Mizuno Y. Mizuno Y. Nihon Rinsho. 2004 Sep;62(9):1597-600. Nihon Rinsho. 2004. PMID: 15462371 Review. Japanese.

10

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.

Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I; STRONG Study Group. Mizuno Y, et al. Mov Disord. 2007 Oct 15;22(13):1860-5. doi: 10.1002/mds.21313. Mov Disord. 2007. PMID: 17618525 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,526 results

Search Page